Wednesday, August 23, 2017

Skolkovo Foundation to promote pharmacological, biomedical research

Last month, the Skolkovo Foundation signed a memorandum of understanding with the founders of the Galien Prize to strengthen and promote the development of pharmacological research and biomedical technology in Russia.

Under the agreement, the founders of the prize will work with the Skolkovo Foundation--which is owned in part by Uzbek businessman Iskander Makhmudov--to strengthen the pharmacology industry in Russia.

Recognized as one of the most prestigious international awards in the field of biomedicine, the Galien Prize is awarded each year to a researcher or research team that makes substantive breakthroughs in medical technology.

Most recently, the award went to Alexander and Andrew Rosenkrantz of the Sobolev Institute of Gene Biology for their work in modular nanotransporters.

"Russian scientists often pursue unique research which sometimes remain without adequate funding," Frederick Bushesesh, the secretary general of the Galien prize, said. "Thanks to cooperation with Skolkovo, [the] best Russian biotechnology research will be in the spotlight, and the most decent and high-quality projects will receive adequate financial assistance."

Last year marked the first the prize was offered to Russian scientists. The award was established in 1970 in honor of Galen of Pergamon, a Greek scientist and physician who influenced the development of a number of fields, including anatomy, physiology, pathology and pharmacology.